AstraZeneca (AZN) Stock: Bernstein Identifies 37% Upside Potential in Overlooked Segment
Key Takeaways Bernstein maintains “outperform” rating on AZN with £186 price target, representing approximately 37% potential gain from £135.54 closing level The firm anticipates non-oncology

